Drug development

Sebastian Nijman, Chief Scientific Officer, Scenic Biotech, explains why harnessing genetic modifiers holds great potential to address the present drug target vacuum and why every drug developer should care about them. According to the National Institute of Health (NIH), approximately 500 of the many thousands of human diseases have an approved treatment. This disappointing result is […]

Says Lu Rahman, DDW Editor in Chief I’ll admit it’s pretty hard right now to come up with one, let alone multiple reasons to be cheerful. As I write this from my desk in the north of the UK, it’s bitterly cold, our schools have been closed (along with everywhere else you might see another […]

Boehringer Ingelheim has entered a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. The new partnership combines Boehringer Ingelheim’s leading expertise in the field of computer-aided drug design and in silico modelling with Google’s […]

The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the increasing adoption and sophistication of technology will affect companies and patients alike. This article is the second part of a two-part series based on […]

Enveda Biosciences’ $4.9 million seed round of funding will enable the company to grow its medicinal plant dataset, enhance its technologies and algorithms to accelerate natural product drug discovery and advance its lead asset for liver fibrosis through preclinical development. The funding was led by True Ventures, with participation from Wireframe Ventures, Village Global and […]

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the lives of more than 9 […]

Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated their long-term strategic drug discovery and development partnership […]

This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on population health and the innovative […]

Gilead Sciences and Galapagos have agreed to amend their existing arrangement for the commercialisation and development of Jyseleca (filgotinib). This announcement follows a meeting with the US FDA related to the New Drug Application (NDA) for filgotinib in the treatment of rheumatoid arthritis (RA.) Based on the feedback received from the FDA during the NDA review […]

Hummingbird Bioscience, a clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, is collaborating with Tempus, an expert in artificial intelligence and precision medicine. This will drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbour neuregulin 1 (NRG1) fusions. As […]